Luke S Farrow1, Toby O Smith2, George P Ashcroft1, Phyo K Myint3. 1. Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, AB25 2ZD, UK. 2. School of Health Sciences, University of East Anglia, Queen's Building, Norwich Research Park, Norwich, NR4 7TJ, UK. 3. Epidemiology Group, Institute of Applied Health Sciences, University of Aberdeen, Foresterhill, Aberdeen, AB25 2ZD, UK.
Abstract
AIM: To systematically examine and quantify the efficacy and safety of tranexamic acid in hip fracture surgery. METHODS: A systematic literature search was conducted using Medline, EMBASE, AMED, CiNAHL, and the Cochrane Central Registry of Controlled Trials. Two assessors independently screened search outputs for potentially relevant articles which met the eligibility criteria. The primary outcome measure was requirement of post-operative blood transfusion. Risk of bias assessment was performed using the Cochrane Collaboration's risk of bias tool for randomized controlled trials (RCTs) and the ROBINS-I tool for observational studies. Meta-analysis was performed to estimate risk ratio (RR), risk difference (RD) and mean difference (MD) values for dichotomous and continuous data outcomes, respectively. The interpretation of each outcome was made using the GRADE approach. RESULTS: Of 102 studies identified, seven met the inclusion criteria including a total of 770 participants (TXA: 341; Control: 429). On meta-analysis, intravenous TXA resulted in a 46% risk reduction in blood transfusion requirement compared to a placebo/control group (RR: 0.54; 95% CI: 0.35-0.85; I2 : 78%; Inconsistency (χ2 ) P = <0.0001; n = 750). There was also a significantly higher post-operative haemoglobin for TXA versus placebo/control (MD: 0.81; 95% CI: 0.45-1.18; I2 : 46%; Inconsistency (χ2 ) P = 0.10; n = 638). There was no increased risk of thromboembolic events (RD: 0.01; 95% CI: -0.03, 0.05; I2 : 68%; Inconsistency (χ2 ) P = 0.007, n = 683). CONCLUSION: There is moderate quality evidence that TXA reduces blood transfusion in hip fracture surgery, with low quality evidence suggesting no increased risk of thrombotic events. These findings are consistent with TXA use in other orthopaedic procedures.
AIM: To systematically examine and quantify the efficacy and safety of tranexamic acid in hip fracture surgery. METHODS: A systematic literature search was conducted using Medline, EMBASE, AMED, CiNAHL, and the Cochrane Central Registry of Controlled Trials. Two assessors independently screened search outputs for potentially relevant articles which met the eligibility criteria. The primary outcome measure was requirement of post-operative blood transfusion. Risk of bias assessment was performed using the Cochrane Collaboration's risk of bias tool for randomized controlled trials (RCTs) and the ROBINS-I tool for observational studies. Meta-analysis was performed to estimate risk ratio (RR), risk difference (RD) and mean difference (MD) values for dichotomous and continuous data outcomes, respectively. The interpretation of each outcome was made using the GRADE approach. RESULTS: Of 102 studies identified, seven met the inclusion criteria including a total of 770 participants (TXA: 341; Control: 429). On meta-analysis, intravenous TXA resulted in a 46% risk reduction in blood transfusion requirement compared to a placebo/control group (RR: 0.54; 95% CI: 0.35-0.85; I2 : 78%; Inconsistency (χ2 ) P = <0.0001; n = 750). There was also a significantly higher post-operative haemoglobin for TXA versus placebo/control (MD: 0.81; 95% CI: 0.45-1.18; I2 : 46%; Inconsistency (χ2 ) P = 0.10; n = 638). There was no increased risk of thromboembolic events (RD: 0.01; 95% CI: -0.03, 0.05; I2 : 68%; Inconsistency (χ2 ) P = 0.007, n = 683). CONCLUSION: There is moderate quality evidence that TXA reduces blood transfusion in hip fracture surgery, with low quality evidence suggesting no increased risk of thrombotic events. These findings are consistent with TXA use in other orthopaedic procedures.
Authors: J L Carson; D G Altman; A Duff; H Noveck; M P Weinstein; F A Sonnenberg; J I Hudson; G Provenzano Journal: Transfusion Date: 1999-07 Impact factor: 3.157
Authors: Valerie A Lawrence; Jeffrey H Silverstein; John E Cornell; Thomas Pederson; Helaine Noveck; Jeffrey L Carson Journal: Transfusion Date: 2003-12 Impact factor: 3.157
Authors: P J Zufferey; M Miquet; S Quenet; P Martin; P Adam; P Albaladejo; P Mismetti; S Molliex Journal: Br J Anaesth Date: 2010-01 Impact factor: 9.166
Authors: Antonio De Vincentis; Astrid Ursula Behr; Giuseppe Bellelli; Marco Bravi; Anna Castaldo; Lucia Galluzzo; Giovanni Iolascon; Stefania Maggi; Emilio Martini; Alberto Momoli; Graziano Onder; Marco Paoletta; Luca Pietrogrande; Mauro Roselli; Mauro Ruggeri; Carmelinda Ruggiero; Fabio Santacaterina; Luigi Tritapepe; Amedeo Zurlo; Raffaele Antonelli Incalzi Journal: Aging Clin Exp Res Date: 2021-07-21 Impact factor: 3.636
Authors: Elizabeth B Gausden; Rameez Qudsi; Myles D Boone; Brian OʼGara; Joseph J Ruzbarsky; Dean G Lorich Journal: J Orthop Trauma Date: 2017-10 Impact factor: 2.512
Authors: Ioannis Gkiatas; Aristeidis-Panagiotis Kontokostopoulos; Spyridon E Tsirigkakis; Ioannis Kostas-Agnantis; Ioannis Gelalis; Anastasios Korompilias; Emilios Pakos Journal: World J Orthop Date: 2022-06-18
Authors: Raj M Amin; Varun Puvanesarajah; Yash P Chaudhry; Matthew J Best; Sandesh S Rao; Steven M Frank; Erik A Hasenboehler Journal: World J Orthop Date: 2021-05-18